Apply to trial NCT04187443

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening